Core Scientific (CORZ) Liabilities and Shareholders Equity (2020 - 2026)

Core Scientific has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $3.1 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $3.1 billion, up 104.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.4 billion (up 111.51% YoY), and the FY2025 annual result was $2.3 billion, up 59.06% from the prior year.
• Liabilities and Shareholders Equity came in at $3.1 billion for Q1 2026 at Core Scientific, up from $2.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.1 billion in Q1 2026 to a low of $664.2 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $1.4 billion (2022), against an average of $1.4 billion.
• Across the five-year window, Liabilities and Shareholders Equity jumped 677.6% in 2022 and tumbled 71.89% in 2023, its largest moves.
• Core Scientific's Liabilities and Shareholders Equity stood at $807.7 million in 2022, then slipped by 11.83% to $712.2 million in 2023, then surged by 107.25% to $1.5 billion in 2024, then jumped by 59.06% to $2.3 billion in 2025, then surged by 30.75% to $3.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $3.1 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.